Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Insulin Delivery

Thoughts on i2O, the Harvard Oral Peptide Delivery Spinout

Here is a brief preview of this blast: A new Harvard spinout called i2O Therapeutics has raised $4M in seed funding from Sanofi Ventures and JDRF T1D Fund. Of note, the company was created with the intention of commercializing a novel oral peptide delivery technology initially directed toward diabetes. Below, FENIX provides insight into why i2O may be using oral insulin development as a stepping stone to other molecules and thoughts on how Sanofi may be leveraging its diabetes expertise without committing to R&D.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.